©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. May 27, 2022; 13(3): 66-71
Published online May 27, 2022. doi: 10.4331/wjbc.v13.i3.66
Published online May 27, 2022. doi: 10.4331/wjbc.v13.i3.66
Progesterone in gender-affirming therapy of trans women
Charalampos Milionis, Ioannis Ilias, Eftychia Koukkou, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, Athens GR-11521, Greece
Author contributions: Milionis C and Ilias I performed the majority of the writing and prepared the table; Ilias I and Koukkou E provided input in writing the paper; Koukkou E coordinated the writing of the paper.
Conflict-of-interest statement: The authors state that they have no conflict of interest to report.
Corresponding author: Ioannis Ilias, MD, PhD, Consultant Physician-Scientist, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, 2, Elena Venizelou Square, Athens GR-11521, Greece. iiliasmd@yahoo.com
Received: December 20, 2021
Peer-review started: December 20, 2021
First decision: February 21, 2022
Revised: February 28, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: May 27, 2022
Processing time: 155 Days and 18.2 Hours
Peer-review started: December 20, 2021
First decision: February 21, 2022
Revised: February 28, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: May 27, 2022
Processing time: 155 Days and 18.2 Hours
Core Tip
Core Tip: The addition of bioidentical progesterone to the gender-affirming treatment of trans women may be beneficial in many ways. However, since relevant studies are lacking, further research is needed.